Biomarkers in Alzheimer's disease drug development

scientific article published on September 21, 2010

Biomarkers in Alzheimer's disease drug development is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/NM.2221
P953full work available at URLhttp://www.nature.com/articles/nm.2221.pdf
http://www.nature.com/articles/nm.2221
P698PubMed publication ID21052077

P2093author name stringKaj Blennow
P2860cites workLewy Body Pathology in Alzheimer's DiseaseQ22241400
The clinical use of structural MRI in Alzheimer diseaseQ24609648
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivoQ24679444
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeuticsQ27860914
A beta oligomers - a decade of discoveryQ29615152
Alzheimer's diseaseQ29616743
Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's diseaseQ30940227
Donepezil effects on cerebral blood flow in older adults with mild cognitive deficitsQ31041952
Alzheimer's disease: clinical trials and drug developmentQ33349401
The neuropathology of probable Alzheimer disease and mild cognitive impairmentQ33616561
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseQ33877903
Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendationsQ33943520
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trialQ33988701
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta reboundQ34036136
Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseQ34098866
Vitamin E and donepezil for the treatment of mild cognitive impairmentQ34411313
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.Q34417339
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individualsQ34727482
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialQ34798154
Mild cognitive impairment: prevalence, prognosis, aetiology, and treatmentQ35172333
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer diseaseQ37192883
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsQ37227424
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous systemQ37316153
The use of PET in Alzheimer diseaseQ37688880
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyQ37699953
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesQ37769104
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trialQ40064054
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyQ40349700
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.Q41989700
Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogsQ42968955
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory studyQ43120526
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled studyQ44336275
Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s DiseaseQ44640384
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.Q45923691
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?Q46412583
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trialQ46616657
Neurochemical dissection of synaptic pathology in Alzheimer's disease.Q47965884
Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusingQ48227034
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.Q48893777
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.Q51867713
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.Q51969054
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.Q51986028
Longitudinal stability of CSF biomarkers in Alzheimer's disease.Q53286684
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectAlzheimer's diseaseQ11081
biomarkerQ864574
P304page(s)1218-1222
P577publication date2010-09-21
P1433published inNature MedicineQ1633234
P1476titleBiomarkers in Alzheimer's disease drug development
P478volume16

Reverse relations

cites work (P2860)
Q57285591A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder
Q42655623Accelerating drug development for Alzheimer's disease through the use of data standards
Q89703430Alleviation of symptoms of Alzheimer's disease by diminishing Aβ neurotoxicity and neuroinflammation
Q34746609An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function
Q91963536Application of Electrochemical Aptasensors toward Clinical Diagnostics, Food, and Environmental Monitoring: Review
Q30651551Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease
Q27021625Blood markers of oxidative stress in Alzheimer's disease
Q59049398CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Q37485864CSF Presenilin-1 complexes are increased in Alzheimer's disease
Q35846251Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort
Q38825497Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice
Q34746995Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Q37022572Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
Q39820325Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future
Q38778638Defeating Alzheimer's disease and other dementias: a priority for European science and society
Q35394390Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture
Q37960496Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease
Q55427595Development and Optimization of a Fluorescent Imaging System to Detect Amyloid-β Proteins: Phantom Study.
Q35910923Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force
Q36071403Evidence for ordering of Alzheimer disease biomarkers
Q33862796Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects
Q24289435Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research
Q92624766HENA, heterogeneous network-based data set for Alzheimer's disease
Q37190009Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints
Q47141112Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics
Q51894031Learning from genetic forms of neurodegeneration.
Q33687554Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease
Q37585625Magnetic resonance imaging for monitoring therapeutic response in a transgenic mouse model of Alzheimer's disease using voxel-based analysis of amyloid plaques
Q38666481Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Q30881333Molecular imaging biomarkers for dementia with Lewy bodies: an update
Q42111862Molecular interactions of Alzheimer's biomarker FDDNP with Aβ peptide
Q82769587Neurodegeneration and the neuroimmune system
Q82769596Neurodegeneration and the neurovascular unit
Q38127470Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.
Q38101555Perspectives on episodic-like and episodic memory
Q27001550Platelets and Alzheimer's disease: Potential of APP as a biomarker
Q36055870Posterior Cingulate Lactate as a Metabolic Biomarker in Amnestic Mild Cognitive Impairment.
Q38053449Potential sources of interference on Abeta immunoassays in biological samples
Q38704916Rethinking on the concept of biomarkers in preclinical Alzheimer's disease
Q94521330SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease
Q57971994Searching for biomarkers in neurodegeneration
Q36677361Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
Q49121401Specific self-monitoring of metal-associated amyloid-β peptide disaggregation by a fluorescent chelator
Q30396334The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications
Q52644601The Past and the Future of Alzheimer's Disease Fluid Biomarkers.
Q82318245The benefits and limitations of animal models for translational research in neurodegenerative diseases
Q38907580The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
Q34026317The future of blood-based biomarkers for Alzheimer's disease
Q26781635The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events
Q26853347The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease
Q38530095Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease
Q59800332Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer’s Disease in the Aging Brain
Q53446502Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.
Q83088740Use of biomarkers in clinical trials of Alzheimer disease: from concept to application
Q53396427White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.